Belgium· BE-AMP-SAM662149-00
Spexotras 0.05 mg/ml
A trametinib product containing trametinib dimethyl sulfoxide, registered in Belgium by Novartis Europharm. The same ATC class is registered in 12 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Trametinib is registered in 12 of 19 countries.
Countries holding a registration under ATC L01EE01 (trametinib), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 7 of them publish a price we can compare per daily dose
Trametinib · ATC L01EE01
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of trametinib costs, country by country.
Normalised to the WHO defined daily dose (2 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Trametinib · price per daily dose (2 mg)
USD · FX 28 Sept 2026
- CH Switzerland$215.55
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Trametinib Dimethyl Sulfoxide
- Manufacturer
- Novartis Europharm
- Country
- Belgium (BE)
- ATC code
- L01EE01
- ATC class
- Trametinib
- Defined daily dose
- 2 mg, O
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
- be_apb4783296
- be_apb7746472
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
22 interactions on record for trametinib.
Graded by severity as the source publishes them — 22 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Trametinib · interactions on record
22 records
- 22 moderate
Most severe, free to view
- FostamatinibB02BX09moderate
- ElagolixH01CC03moderate
- SarecyclineJ01AA14moderate
- IsavuconazoleJ02AC05moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Trametinib in 4 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/6a7747ed-e603-4b34-b612-6f91fbc99499 GET /v1/drugs/6a7747ed-e603-4b34-b612-6f91fbc99499?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Powder for oral solution",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Spexotras 0.05 mg/ml",
"name_fr": "Spexotras 0.05 mg/ml",
"name_nl": "Spexotras 0.05 mg/ml",
"amp_code": "SAM662149-00",
"strengths": [
"4.7000",
"4.7000",
"100.0000",
"0.8000",
"1.9800"
],
"pack_count": 1,
"substances": [
"Trametinib Dimethyl Sulfoxide",
"Trametinib",
"Betadex Sulfobutyl Ether Sodium",
"Methyl Parahydroxybenzoate",
"Potassium Sorbate",
"Sodium"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Trametinib",
"authorisation_numbers": [
"EU/1/23/1781/001"
]
}See everything about trametinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.